Carregant...

Acquired resistance to ABT-737 in lymphoma cells that up-regulate MCL-1 and BFL-1

ABT-737 is a small-molecule antagonist of BCL-2 currently under evaluation in clinical trials in the oral form of ABT-263. We anticipate that acquired resistance to this promising drug will inevitably arise. To study potential mechanisms of resistance to ABT-737, we derived resistant lines from init...

Descripció completa

Guardat en:
Dades bibliogràfiques
Autors principals: Yecies, Derek, Carlson, Nicole E., Deng, Jing, Letai, Anthony
Format: Artigo
Idioma:Inglês
Publicat: American Society of Hematology 2010
Matèries:
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC2858493/
https://ncbi.nlm.nih.gov/pubmed/20197552
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/blood-2009-07-233304
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!